IMNM - Immunome, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$36.20
DETAILS
HIGH:
$40.00
LOW:
$32.00
MEDIAN:
$36.00
CONSENSUS:
$36.20
UPSIDE:
67.13%
About Immunome, Inc. (https://immunome.com)
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Clay Siegall | Chairman, President & Chief Executive Officer | 1961 | $1,409,791 USD |
| Max Rosett | Chief Financial Officer | 1990 | $1,162,467 USD |
| Jack Higgins | Chief Scientific Officer | 1980 | $956,342 USD |
| Robert J. Lechleider | Chief Medical Officer | 1961 | $850,093 USD |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | 1973 | $715,350 USD |
| Kinney Horn | Chief Business Officer | 1975 | $598,862 USD |
| Philip Tsai | Chief Technical Officer | 1968 | – |
| Roee Shahar | Executive Vice President of Commercial | – | – |